Dannielle Appelhans
Director/Board Member at GENERATION BIO CO.
Net worth: 60 200 $ as of 2024-04-29
Dannielle Appelhans active positions
| Companies | Position | Start | End |
|---|---|---|---|
| GENERATION BIO CO. | Director/Board Member | 2022-07-14 | - |
Cour Pharmaceuticals Development Co., Inc.
 Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Chief Operating Officer | 2023-07-18 | - |
Career history of Dannielle Appelhans
Former positions of Dannielle Appelhans
| Companies | Position | Start | End |
|---|---|---|---|
| RUBIUS THERAPEUTICS | Chief Executive Officer | 2022-11-14 | 2023-03-02 |
| Chief Operating Officer | 2021-08-08 | 2022-11-14 | |
| President | 2022-11-14 | 2023-03-02 | |
| AVEXIS INC | Chief Tech/Sci/R&D Officer | 2019-12-31 | 2020-12-31 |
Training of Dannielle Appelhans
| MIT Sloan School of Management | Masters Business Admin |
| University of Michigan | Undergraduate Degree |
| Massachusetts Institute of Technology | Graduate Degree |
Statistics
International
| United States | 8 |
Operational
| Chief Operating Officer | 2 |
| Chief Executive Officer | 1 |
| President | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| GENERATION BIO CO. | Health Technology |
| Private companies | 3 |
|---|---|
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Cour Pharmaceuticals Development Co., Inc.
Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Health Technology |
- Stock Market
- Insiders
- Dannielle Appelhans
- Experience
